Needham Reiterates Buy on Vir Biotechnology, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Vir Biotechnology (NASDAQ:VIR) and maintained a price target of $19.
November 01, 2024 | 10:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Vir Biotechnology and maintained a price target of $19, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $19 price target by a reputable analyst suggests positive sentiment and confidence in Vir Biotechnology's future performance. This could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100